A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Hidetoshi Hayashi, Kakuhiro Yamaguchi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Kazuo Hasegawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science